Market Intelligence, Clinical Progress, and High-Purity Reagents for Primary Hyperoxaluria Type 1 (PH1) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AGXT drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AGXT Wild-Type & Pathogenic Mutant Recombinant Proteins (G170R, I244T, F152I, G41R) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. PLP cofactor binding site preserved. |
View AGXT Products |
| Gene Delivery | AGXT Promise-ORF / Lentivirus Premade Particles Full-length ORF with native peroxisomal targeting signal (PTS1) or optional mitochondrial targeting sequence (MTS) variants for subcellular localization studies. |
View AGXT Products |
| Benchmark Ab | Anti-AGXT Recombinant Antibody (Rabbit Monoclonal, Sequence Verified) For Western blot, IP, ELISA, and immunohistochemistry. |
View AGXT Products |
| Validator | AGXT siRNA Set For knockdown verification and specificity controls in PH1 cell models. |
View AGXT Products |
| Related Target: HAO1 | HAO1 (Glycolate Oxidase) Upstream enzyme in oxalate synthesis; target of Lumasiran (approved RNAi therapy). |
View HAO1 Products |
| Related Target: GRHPR | GRHPR (Glyoxylate Reductase/Hydroxypyruvate Reductase) Parallel glyoxylate metabolism pathway; compensatory target for PH2 counter-screening. |
View GRHPR Products |
| Related Target: LDHA | LDHA (Lactate Dehydrogenase A) Oxalate synthesis via glyoxylate reduction; target of Nedosiran (approved RNAi therapy). |
View LDHA Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pathogenic mutant folding & stability (e.g., G170R, I244T) | Human WT + Disease Mutants (G170R, I244T, F152I, G41R) available; Sequence Verified; Theoretical MW confirmed by Mass Spec; High Purity (>95%) for thermal shift and chaperone binding assays. |
| Subcellular localization & trafficking (Peroxisomal vs. Mitochondrial) | Full-length ORF Lentivirus with native PTS1 or MTS variants; HEK293-expressed proteins preserve proper folding for organellar co-localization studies. |
| Enzyme activity & PLP cofactor binding | Active protein with preserved PLP-binding lysine (K242); Suitable for spectrophotometric activity assays (glyoxylate to glycine conversion) and PLP-binding kinetics. |
| Off-target selectivity & assay standardization | Validated siRNA and sequence-verified antibody included; Homologous protein panels (HAO1, GRHPR, LDHA) available for cross-reactivity screening. |
Live AGXT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Chaperone Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The therapeutic landscape for Primary Hyperoxaluria Type 1 (PH1) is transitioning from conservative management and liver transplantation toward precision genetic medicines. First-generation RNAi therapies (Lumasiran targeting HAO1, Nedosiran targeting LDHA) have validated the substrate-reduction strategy, but do not address the root cause of AGXT deficiency. The next wave of R&D focuses on direct AGXT restoration via three major modalities: (1) pharmacological chaperones to stabilize misfolded mutants (e.g., I244T, G170R); (2) gene therapy (AAV-based) to deliver a functional AGXT gene to hepatocytes; and (3) mRNA replacement therapy (LNP-delivered) to enable transient AGXT protein production. Combination approaches that pair AGXT restoration with substrate reduction are anticipated to define future standard of care for refractory patients.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Chaperones | Academic/Biotech Consortiums | PH1 (I244T+ and other missense mutations) | Thermal Shift Assay (Need high-purity WT and mutant proteins) |
| Gene Therapy (AAV) | LogicBio (acquired), Generation Bio, Beam Therapeutics | PH1 (All genotypes) | Functional Enzyme Activity Assay (Need active AGXT antigen for potency testing and lentivirus for in vitro modeling) |
| mRNA Therapy | Moderna, Vertex, Arcturus Therapeutics | PH1 | Cell-based Expression Validation (Need Lentivirus ORF for stable cell line construction and anti-AGXT antibodies) |
| Substrate Reduction (RNAi) | Alnylam (HAO1), Novo Nordisk/Dicerna (LDHA) | PH1/PH2 | Pathway Cross-validation (Need AGXT + HAO1 + LDHA protein panels) |